Quarterly ResultMay 7, 2026, 04:18 PM
Globus Medical Q1 Net Sales $759.9M, EPS $0.90; Raises 2026 EPS Guidance
AI Summary
Globus Medical reported strong financial results for the first quarter ended March 31, 2026, with worldwide net sales increasing 27.0% to $759.9 million and GAAP diluted EPS rising 66.6% to $0.90. Non-GAAP diluted EPS also saw a significant increase of 64.7% to $1.12. The company also updated its full-year 2026 non-GAAP diluted EPS guidance, raising it to a range of $4.70 to $4.80 from the previous $4.40 to $4.50, while reaffirming its revenue guidance.
Key Highlights
- Globus Medical raised full-year 2026 non-GAAP diluted EPS guidance to $4.70-$4.80 from $4.40-$4.50.
- Q1 2026 worldwide net sales increased 27.0% to $759.9 million.
- Q1 2026 GAAP diluted EPS was $0.90, an increase of 66.6% year-over-year.
- Q1 2026 non-GAAP diluted EPS was $1.12, an increase of 64.7% year-over-year.
- Base business net sales, excluding Nevro, increased 13.2% to $677.2 million.
- The Nevro acquisition contributed $82.7 million to Q1 2026 net sales.
- US net sales for Q1 2026 increased by 25.0% compared to Q1 2025.
- International net sales increased 35.6% (27.8% constant currency) in Q1 2026.
- The company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion.